Dilara M Mccauley

US Patent:

7919519, Apr 5, 2011

Filed:

Mar 21, 2007

Appl. No.:

11/726351

Inventors:

Roland Burli - Pasadena CA, US
Victor J. Cee - Thousand Oaks CA, US
Jennifer Golden - Simi Valley CA, US
Brian Alan Lanman - Oak Park CA, US
Susana Neira - Thousand Oaks CA, US
Ashis Saha - Stow MA, US
Nili Schutz - Tel-Aviv, IL
Xiang Yu - Acton MA, US
Dilara McCauley - Cambridge MA, US
Mercedes Lobera - Bolton MA, US
Yael Marantz - Kadima, IL
Jian Lin - Walpole MA, US
Srinivasa R. Cheruku - Lexington MA, US
Pini Orbach - Needham MA, US
Anurag Sharadendu - Washington DC, US
Robert C. Penland - Watertown MA, US
Kimberley Gannon - Watertown MA, US
Sharon Shacham - Newton MA, US
Silvia Noiman - Herzliyya, IL
Oren Becker - Mevaseret Zion, IL
Zhaoda Zhang - Andover MA, US

Assignee:

Epix Pharmaceuticals Inc. - Lexington MA

International Classification:

A61K 31/404
A61K 31/381
A61K 31/343
C07D 209/12
C07D 333/56
C07D 307/80

US Classification:

514419, 514443, 514469, 548494, 549 58, 549469

Abstract:

The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e. g. , for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.

US Patent:

8236773, Aug 7, 2012

Filed:

Feb 14, 2006

Appl. No.:

11/884411

Inventors:

Claude Benedict - Cambridge MA, US
David Epstein - Huntington NY, US
Charles Wilson - Concord MA, US
Dilara McCauley - Cambridge MA, US
Jeffrey Kurz - Winchester MA, US
Markus Kurz - Basel, CH
Thomas Greene McCauley - Cambridge MA, US
James Rottman - Sudbury MA, US

Assignee:

Archemix LLC - San Francisco CA

International Classification:

C12N 15/11

US Classification:

514 44A

Abstract:

The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.

US Patent:

8436164, May 7, 2013

Filed:

Jun 18, 2012

Appl. No.:

13/525680

Inventors:

Claude Benedict - Cambridge MA, US
David Epstein - Huntington NY, US
Charles Wilson - Concord MA, US
Dilara McCauley - Cambridge MA, US
Jeffrey Kurz - Winchester MA, US
Markus Kurz - Basel, CH
Thomas Greene McCauley - Cambridge MA, US
James Rottman - Sudbury MA, US

Assignee:

Archemix LLC - San Francisco CA

International Classification:

C07H 21/04

US Classification:

536 245

Abstract:

The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.

US Patent:

8569259, Oct 29, 2013

Filed:

Nov 16, 2007

Appl. No.:

12/515033

Inventors:

Efrat Ben-Zeev - K. Motzkin, IL
Vincent Jacques - Somerville MA, US
Yael Marantz - Kadma, IL
A. Sekar Reddy - Burlington MA, US
Zhaoda Zhang - Andover MA, US
Oren Becker - Mevaseret Zion, IL
Dilara McCauley - Cambridge MA, US
Pini Orbach - Tel Mond, IL
Sharon Shacham - Chestnut Hill MA, US
Ashis K. Saha - Stow MA, US
Michael Xie - Natick MA, US

Assignee:

Microdose Therapeutx, Inc. - Monmouth Junction NJ

International Classification:

A61K 31/70
A01N 43/04
C07H 19/00
C07H 19/04
C07H 19/20

US Classification:

514 45, 514 47, 536 262, 536 2622

Abstract:

Provided are adenosine analog compounds of the general formula that act as P2Y receptors, e. g. , the P2Yreceptor, including pharmaceutical compositions; and uses thereof to treat or prevent diseases associated with that receptor, e. g. , disorders relating to mucus secretion, such as cystic fibrosis, chronic obstructive pulmonary disorder (COPD), asthma, constipation, chronic idiopathic constipation, dry mouth (xerostomia), gum disease, and gastrointestinal problems caused by radiation and chemotherapy for cancer.

US Patent:

20070048248, Mar 1, 2007

Filed:

Feb 14, 2006

Appl. No.:

11/354657

Inventors:

Claude Benedict - Cambridge MA, US
David Epstein - Belmont MA, US
Dilara McCauley - Cambridge MA, US
Jeffrey Kurz - Arlington MA, US
Markus Kurz - Newton MA, US
Thomas McCauley - Cambridge MA, US
James Rottman - Sudbury MA, US
Charles Wilson - Concord MA, US

International Classification:

A61K 48/00

US Classification:

424078300, 514044000

Abstract:

The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.

US Patent:

20070173487, Jul 26, 2007

Filed:

Jul 24, 2006

Appl. No.:

11/491766

Inventors:

Ashis K. Saha - Stow MA, US
Nili Schutz - Tel-Aviv, IL
Anurag Sharadendu - Bedford NH, US
Dilara McCauley - Cambridge MA, US
Mercedes Lobera - Concord MA, US
Yael Marantz - Kadima, IL
Jian Lin - Walpole MA, US
Srinivasa Rao Cheruku - Lexington MA, US
Pini Orbach - Needham MA, US
Anurag Sharadendu - Bedford MA, US
Robert Christian Penland - Watertown MA, US
Kimberley Gannon - Watertown MA, US
Sharon Shacham - Newton MA, US
Silvia Noiman - Herzliyya, IL
Oren Becker - Mevaseret Zion, IL

International Classification:

A61K 31/452
A61K 31/397
C07D 405/02

US Classification:

51421019, 514320, 548950, 546196

Abstract:

The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behcet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.

US Patent:

20090053138, Feb 26, 2009

Filed:

Nov 2, 2005

Appl. No.:

11/666954

Inventors:

Jeffrey Preiss - Cambridge MA, US
Charles Wilson - Concord MA, US
Martin Stanton - Concord MA, US
John Diener - Cambridge MA, US
David Epstein - Huntington NY, US
Dilara McCauley - Cambridge MA, US
Thomas McCauley - Cambridge MA, US

International Classification:

A61K 49/00
C07H 21/04
A61P 35/00
A61K 31/711

US Classification:

424009100, 536023100, 514044000

Abstract:

Materials and methods are provided for producing and using aptamers as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and/or VEGF receptor or any combination thereof with affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptamers having one or more CpG motifs embedded therein or appended thereto.

US Patent:

20100184749, Jul 22, 2010

Filed:

Oct 12, 2007

Appl. No.:

12/445149

Inventors:

Merav Fichman - Modi'in, IL
Rosa E. Melendez - Woburn MA, US
Pradyumna Mohanty - Woburn MA, US
Jian Lin - Walpole MA, US
Dilara McCauley - Cambridge MA, US
Boaz Inbal - Kfar Shmuel, IL
Mercedes Lobera - Bolton MA, US
Pini Orbach - Tel Mond, IL
Ori Kalid - Tel Aviv, IL
Dongli Chen - Brighton MA, US
Yael Marantz - Kadima, IL
Michael Xie - Natick MA, US
Sharon Shacham - Chestnut Hill MA, US
Oren Becker - Mevaseret Zion, IL

Assignee:

EPIX Delaware ,Inc. - Lexington MA

International Classification:

A61K 31/549
C07D 417/06
A61P 37/06
A61P 17/06
A61P 19/02
A61P 9/10
A61P 11/00
A61P 13/12
A61P 1/16
A61P 3/10

US Classification:

5142228, 544 11

Abstract:

Chemokine receptor antagonists, in particular, compounds of Formula (I) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein.